Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug2688 | On-line exercise and education Wiki | 0.45 |
| drug1996 | Intra-articular corticosteroid injection Wiki | 0.45 |
| drug3671 | Software Messaging Wiki | 0.45 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1618 | Gait Retraining Wiki | 0.45 |
| drug1364 | Electrotherapy group Wiki | 0.45 |
| drug1559 | Flywheel exercise Wiki | 0.45 |
| drug1171 | Ddrops® products, 50,000 IU, Oral Wiki | 0.45 |
| drug2689 | On-site exercise and education Wiki | 0.45 |
| drug1746 | Home exercise Wiki | 0.32 |
| drug637 | Breath Biopsy face masks with removable filters and fitted PVA strip Wiki | 0.32 |
| drug4253 | Vitamin D3 Wiki | 0.18 |
| drug1030 | Control Wiki | 0.12 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D010003 | Osteoarthritis, NIH | 0.55 |
| D015207 | Osteoarthritis, Hip NIH | 0.45 |
| D025241 | Spondylarthritis NIH | 0.26 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0005086 | Knee osteoarthritis HPO | 1.00 |
| HP:0002758 | Osteoarthritis HPO | 0.55 |
| HP:0008843 | Hip osteoarthritis HPO | 0.45 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0002355 | Difficulty walking HPO | 0.20 |
| HP:0012532 | Chronic pain HPO | 0.12 |
| HP:0001369 | Arthritis HPO | 0.10 |
Navigate: Correlations HPO
There are 5 clinical trials
Osteoarthritis (OA) is a condition affecting the whole joint and is a major cause of pain and disability worldwide. Although OA is very common, the initial steps which lead to the development of pain and tissue damage are not fully understood. In this study participants will be investigated for markers in the blood, joint and urine in people who have a diagnosis of osteoarthritis or inflammatory arthritis and are receiving a steroid injection for their condition. Markers will be evaluated in participants with osteoarthritis compared with other types of arthritis, including rheumatoid arthritis and spondyloarthritis.
Description: Pain outcome measure. The Numerical Rating Scale for pain has a range of 0 - 10, with the lowest score being 0 and the highest rating at 10.The pain rating will be reported by the participants for their symptomatic knee
Measure: Change from Baseline Numerical Rating Scale (NRS) for pain in target knee after 3 months Time: Baseline (Visit 1) and 3 months after treatment (Visit 2)Description: Protein measurements in serum, urine and synovial fluid for type II collagen degradation products in the samples. The levels of type II collagen degradation products may range from 0 to greater than 500 ng/mmol, depending on the stage and severity of the condition
Measure: Change in Biomarkers 3 months following treatment Time: Baseline (Visit 1) and 3 months after treatment (Visit 2)This study investigates the feasibility of a gait-retraining program for older adults with knee osteoarthritis. The study will enroll 40 participants, with 20 receiving a gait retraining intervention and 20 receiving a graded walking program without gait retraining.
Description: # of participants screened per month
Measure: Recruitment rate Time: through study completion, an average of 2 yearsDescription: # of participants enrolled per month
Measure: Enrollment rate Time: through study completion, an average of 2 yearsDescription: % participants that complete all study visits
Measure: Retention Time: through study completion, an average of 2 yearsDescription: Proportion of participants who withdraw or terminated by investigators and reasons why
Measure: Withdrawals/Terminated Time: through study completion, an average of 2 yearsDescription: Proportion of participants with AE/UP
Measure: Adverse events (AE)/Unanticipated problems (UP) Time: through study completion, an average of 2 yearsDescription: Slope of the most linear portion of the vertical ground reaction force curve, during early stance.
Measure: Vertical average loading rate Time: Change from baseline to conclusion of intervention, an average of 1-monthDescription: Maximum slope of the most vertical portion of the vertical ground reaction force curve between successive data points, during early stance.
Measure: Vertical instantaneous loading rate Time: Change from baseline to conclusion of intervention, an average of 1-monthDescription: WOMAC questionnaire, pain sub scale 0-20
Measure: Knee Pain with Activities Time: Change from baseline to conclusion of intervention, an average of 1-monthDescription: Visual analog scale, 0-100
Measure: Knee Pain Severity Time: Change from baseline to conclusion of intervention, an average of 1-monthDescription: Assessed using hand held algometer
Measure: Pressure pain threshold Time: Change from baseline to conclusion of intervention, an average of 1-monthThis study aims to 1) observe the course of pain, 2) mental status, and 3) possible effect of a behavioral intervention delivered via an automated mobile phone messaging robot in patients were indicated and/or scheduled to undergo joint replacement but have been cancelled or delayed due to the COVID-19 crisis.
Description: PROMIS Pain Intensity 3A short form is a 3 question survey measuring an individual's pain over the past 7 days. It utilizes a scale of 1 (no pain) to 5 (very severe pain) for all questions. The scores for the 3 questions are summed and then matched to a corresponding t-score for the instrument. The corresponding t-score is the final, reportable score and can range from 30.7 to 71.8 for the PROMIS Pain Intensity 3A instrument. Higher t-score values represent worse pain outcomes. More information on this instrument, including a scoring manual, can be found at http://www.healthmeasures.net
Measure: Change in reported pain intensity score (PROMIS Pain Intensity 3A) Patient-reported outcomes measurement information system Pain Intensity (PROMIS) 3A short form scores collected from all participating subjects. Time: Measurements assessed via a computer interface of the standardized form listed above on the day of enrollment and on day fourteen, via telephone.Description: PROMIS Pain Intensity 1A short form is a 1 question survey measuring an individual's average pain over the past 7 days. It utilizes a scale of 0 (no pain) to 10 (worst imaginable pain). Higher values represent worse pain outcomes. More information on this instrument, including a scoring manual, can be found at http://www.healthmeasures.net
Measure: Change in reported pain intensity score (PROMIS Pain Intensity 1A) Patient-reported outcomes measurement information system Pain Intensity (PROMIS) 1A short form scores collected from all participating subjects. Time: Measurements assessed via a computer interface of the standardized form listed above on the day of enrollment and on day fourteen, via telephone.Description: The PROMIS Pain Interference 8A short form is an 8 question survey that measures how much pain has interfered in the respondent's life over the past 7 days. It utilizes a scale of 1 (not at all) to 5 (very much) for all questions. The scores for all 8 questions are summed and then matched to a corresponding t-score for the instrument. The corresponding t-score is the final, reportable score and can range from 40.7 to 77.0 for the PROMIS Pain Interference 8A instrument. Higher t-score values represent worse pain interference outcomes. More information on this instrument, including a scoring manual, can be found at http://www.healthmeasures.net
Measure: Change in reported pain interference score Patient-reported outcomes measurement information system (PROMIS) Pain Interference 8A short form scores collected from all participating subjects. Time: Measurements assessed via a computer interface of the standardized form listed above on the day of enrollment and on day fourteen, via telephone.Description: The PROMIS Emotional Distress-Anxiety 8A short form is an 8 statement survey that measures how much emotional distress, specifically due to anxiety, a respondent has experienced over the past 7 days. It utilizes a scale of 1 (never) to 5 (always) for all the statements. The scores for all 8 statements are summed and then matched to a corresponding t-score for the instrument. The corresponding t-score is the final, reportable score and can range from 37.1 to 83.1 for the PROMIS Emotional Distress-Anxiety 8A instrument. Higher t-score values represent worse anxiety caused emotional distress outcomes. More information on this instrument, including a scoring manual, can be found at http://www.healthmeasures.net
Measure: Change in reported emotional distress (anxiety) score. Patient-reported outcomes measurement information system (PROMIS) Emotional Distress-Anxiety 8A short form scores collected from all participating subjects. Time: Measurements assessed via a computer interface of the standardized form listed above on the day of enrollment and on day fourteen, via telephone.Due to enforced social distancing as a direct consequence of the COVID-19 pandemic, many on-site health care services are unavailable. This study seeks to investigate the relative effectiveness of an alternative on-line delivery model of exercise and education compared to on-site delivery in patients with knee osteoarthritis.
Description: Summary score from the Knee injury and Osteoarthritis Outcome Score, short version (KOOS 12). The summary score is calculated as the average score from the KOOS 12 subscales pain, function and quality of life (QOL), ranging from 0 (worst) to 100 (best).
Measure: Knee impact summary Time: Primary follow-up point: Change from baseline to completion of GLA:D program (an average of three months). Secondary follow-up point: 12 monthsDescription: Fast-paced walking ability is recorded by the physiotherapists and evaluated using the 40-m fast-paced walk test.
Measure: Fast-paced walking ability Time: Primary follow-up point: Change from baseline to completion of GLA:D program (an average of three months)Description: Chair-stand ability is recorded by the physiotherapists and evaluated using the 30-s chair-stand test.
Measure: Chair-stand ability Time: Primary follow-up point: Change from baseline to completion of GLA:D program (an average of three months)Description: Patients self-report of function during daily life using the subscale function from the KOOS 12 questionnaire with scores ranging from 0 (worst) to 100 (best).
Measure: Self-reported function Time: Primary follow-up point: Change from baseline to completion of GLA:D program (an average of three months). Secondary follow-up point: 12 monthsDescription: Patients self-report of pain using the subscale pain from the KOOS 12 questionnaire with scores ranging from 0 (worst) to 100 (best).
Measure: Self-reported pain Time: Primary follow-up point: Change from baseline to completion of GLA:D program (an average of three months). Secondary follow-up point: 12 monthsDescription: Patients self-report of quality of life using the subscale quality of life from the KOOS 12 questionnaire with scores ranging from 0 (worst) to 100 (best).
Measure: Self-reported quality of life Time: Primary follow-up point: Change from baseline to completion of GLA:D program (an average of three months). Secondary follow-up point: 12 monthsDescription: Mean pain intensity during the last week in the most affected knee is evaluated on a 100 mm visual analogue scale (VAS) with terminal descriptors of 'no pain' (0 mm) and 'maximum pain' (100 mm).
Measure: Pain intensity Time: Primary follow-up point: Change from baseline to completion of GLA:D program (an average of three months). Secondary follow-up point: 12 monthsDescription: Patients self-report of time spent (frequency and duration) on structured physical activity and exercise.
Measure: Physical activity and exercise Time: Primary follow-up point: Change from baseline to completion of GLA:D program (an average of three months). Secondary follow-up point: 12 monthsDescription: Patients self-report of satisfaction with the GLA:D program.
Measure: Patient satisfaction Time: Primary follow-up point: Completion of GLA:D program (an average of three months). Secondary follow-up point: 12 monthsDescription: Patients self-reporting if, how and where they have continued exercising.
Measure: Continuation of exercise Time: Follow-up point: 12 monthsDescription: Patients self-report their current activity levels using the University of California, Los Angeles (UCLA) activity scale, ranging from 1 (inactive, dependent on others) to 10 (regular participation in high-impact sports).
Measure: Self-reported activity levels Time: Primary follow-up point: Change from baseline to completion of GLA:D program (an average of three months). Secondary follow-up point: 12 monthsDescription: Patients self-report of use of acquired skills and knowledge from the GLA:D program.
Measure: Usage of what was learned during GLA:D Time: Primary follow-up point: Completion of GLA:D program (an average of three months). Secondary follow-up point: 12 monthsDescription: Patients self-report of how they handle flare-ups in their knee OA symptoms.
Measure: Symptom management Time: Primary follow-up point: Change from baseline to completion of GLA:D program (an average of three months). Secondary follow-up point: 12 monthsDescription: Intake of painkillers is evaluated by the physiotherapist asking the patients about intake of any joint related medication. If taking painkillers, the patients are asked which type and whether or not they were taken because of their knee pain.
Measure: Intake of pain killers Time: Primary follow-up: Change from baseline to completion of GLA:D program (an average of three months).Description: Patients self-report of sick leave due to knee symptoms.
Measure: Sick leave Time: Follow-up points: Baseline and 12 monthsDescription: Patients self-report of their health situation using EuroQol, 5 dimensions, 5 levels (EQ-5D-5L) score (-0.624 to 1; worst to best).
Measure: Health-related quality of life, index score Time: Primary follow-up point: Change from baseline to completion of GLA:D program (an average of three months). Secondary follow-up point: 12 monthsDescription: Patients self-report of their health situation using the EuroQol visual analogue scale (EQ VAS), ranging from 0-100 (worst to best).
Measure: Health-related quality of life, visual analogue scale Time: Primary follow-up point: Change from baseline to completion of GLA:D program (an average of three months). Secondary follow-up point: 12 monthsDescription: Patients self-report of current knee condition compared to before participation in GLA:D, scored on a 7-point likert scale (much worse to much better).
Measure: Global perceived effect Time: Primary follow-up point: Completion of GLA:D program (an average of three months). Secondary follow-up point: 12 monthsDescription: Patients self-report of pain during each exercise session, rated using a numeric pain rating scale (NPRS) 0-10, with zero representing no pain and 10 representing extreme pain.
Measure: Pain during exercise (only for on-line group) Time: Immediately prior to, and immediately after each exercise sessionThe main purpose of the study is to examine the effect of squat-based exercise approach in individuals with knee osteoarthritis. The aim of this study is to compare effect to three groups (flywheel exercise group, electrotherapy modality group and home exercise group) and also decrease the pain, increase muscle strength, activation values and increase the functional level of individuals. Osteoarthritis is the most common rheumatological disease in the world that primarily results in progressive cartilage destruction. Changes occurring as a result of osteoarthritis are the main cause of disability and are most common in the knee joint. Osteoarthritis; problems such as pain, tenderness, joint stiffness, joint swelling, movement restriction, joint deformities, loss of muscle strength, decreased functional capacity and impaired quality of life are observed. The daily life activities of individuals with knee osteoarthritis are restricted by the problems of walking up and down stairs, getting out of the chair, standing, squatting, walking. Improving the symptoms of the disease is an important goal of the rehabilitation process of patients with knee osteoarthritis. In individuals with knee osteoarthritis, joint structure and deformation in cartilage also show loss of strength with muscles. Strengthening exercises have been used in patients with knee osteoarthritis for a long time. Squat exercise is a type of exercise that is widely used as a strengthening exercise.
Description: The primary outcome measures included the level of function determined by the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) . WOMAC is a specific, valid, reliable criterion for knee osteoarthritis and includes 24 questions under three subheadings: pain, stiffness and physical function. Each question was scored according to the Likert scale as 0 = none, 1 = mild, 2 = moderate, 3 = severe, 4 = very severe.
Measure: Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Time: 10 minutesDescription: EMG-BF (Intelect Advanced Color Combo + EMG, Chattanooga Group, TN, USA) was used to evaluate muscle activation level. The screen scale was used as a visual feedback, as an increased or decreasing signal tone with varying muscle activity as sensory feedback. The undermentioned muscles will be evaluated in study, Rectus femoris Vastus lateralis Vastus medialis Biceps femoris Gastrocnemius
Measure: EMG-BF Time: 10 minutesDescription: A dynamometer was used to evaluate muscle strength. Muscle strength was evaluated in the following muscles, each measurement was made three times and the average was taken. M. Iliopsoas M. Gluteus Maximus M. Gluteus Medius M. Quadriceps Femoris Hamstring muscle group M. Gastrosoleus M. Tibialis Anterior
Measure: Muscle strength Time: 10 minutesDescription: The instrument that measures sensitivity to pain and gives a numerical value is called an algometer. In total, application was made at 4 different points. Medial point of heel - Right Medial point of heel - Left Medial point of knee-Right Medial point of knee-Left Measurements were made three times and averaged.
Measure: Algometer Time: 5 minutesDescription: Purpose and application of the test: The Visual Analog Scale (VAS) is used to convert some values that cannot be measured numerically into numericals. Two end definitions of the parameter to be evaluated are written on both ends of a 100 mm line and the patient is asked to indicate where his condition is appropriate by drawing a line or by placing a point or pointing on this line. Rest, activity and night were evaluated in three different time periods
Measure: Visual Analog Scale (VAS) Evaluation Time: 5 minutesDescription: To determine fall risk and measure the progress of balance, sit to stand and walking.The patient stands up upon therapist's command: walks 3 meters, turns around, walks back to the chair and sits down.
Measure: Time up and go test Time: 20 secondsDescription: The 30 Second Sit to Stand Test is also known as 30 second chair stand test ( 30CST), is for testing leg strength and endurance in older adults.The participant is encouraged to complete as many full stands as possible within 30 seconds. The participant is instructed to fully sit between each stand.
Measure: 30 Seconds Sit To Stand Test Time: 30 SecondsDescription: The individual is asked to climb and descend 7 times. The total time is recorded.
Measure: Step test Time: 1 minuteDescription: Lower extremity joints and range of motion were evaluated. Hip Flexion Hip Extension Hip Internal Rotation Hip External Rotation Knee Flexion Knee Extension Ankle Plantar Flexion Ankle Dorsi Flexion
Measure: goniometer Time: 10 minutesAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports